SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWDPRNewsWire • 07/18/21
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration JournalGlobeNewsWire • 07/09/21
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks DropBenzinga • 06/29/21
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License ApplicationGlobeNewsWire • 06/29/21
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design StudyGlobeNewsWire • 06/09/21
MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/08/21
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021GlobeNewsWire • 04/26/21
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic WoundsGlobeNewsWire • 03/24/21
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin CancerGlobeNewsWire • 02/22/21
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021GlobeNewsWire • 02/16/21
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceGlobeNewsWire • 02/10/21
MediWound Provides Progress Update on Its EscharEx Clinical Development ProgramGlobeNewsWire • 01/11/21
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement AgentGlobeNewsWire • 12/21/20